Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about WVE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| WVE-210201 | Duchenne Muscular Dystrophy | Phase 2/3 · NCT03907072 | Terminated |
| SAD: 30mg WVE-003 | Huntington Disease | Phase 1/2 · NCT05032196 | Completed |
| WVE-004 | ALS | Phase 1/2 · NCT04931862 | Terminated |
| WVE-006 | Alpha-1 Antitrypsin Deficiency | Phase 1/2 · NCT06405633 | Recruiting |
| WVE-007 | Overweight and Obesity | Phase 1/2 · NCT06842186 | Recruiting |
| WVE-120101 | Huntington's Disease | Phase 1/2 · NCT03225833 | Terminated |
| WVE-120102 | Huntington's Disease | Phase 1/2 · NCT03225846 | Terminated |
| WVE-N531 | Duchenne Muscular Dystrophy | Phase 1/2 · NCT04906460 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
WVE holds $431M in cash and short-term investments (as of Sep 30, 2026) and burns about $56.9M/quarter from operations, an estimated runway of 22.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when WVE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. Director, 10% owner · +140,200 options |
Insider | 26,975,505 | 13.68% | 2026-10-05 |
| GSK plc 10% owner |
Insider | 18,245,691 | 9.25% | 2025-12-11 |
| Ken Takanashi Director · +140,200 options |
Insider | 9,637,187 | 4.89% | 2026-10-05 |
| Chandra Vargeese Chief Technology Officer, Head of Platfo · +273,750 options |
Insider | 408,246 | 0.21% | 2026-02-05 |
| Gregory L. Verdine Director · +64,000 options |
Insider | 275,917 | 0.14% | 2026-10-05 |
| Paul Bolno President and CEO, Director · +1.00M options |
Insider | 275,520 | 0.14% | 2026-02-05 |
| Kyle Moran Chief Financial Officer · +571,450 options |
Insider | 134,385 | 0.07% | 2026-02-05 |
| Erik Ingelsson Chief Scientific Officer |
Insider | 87,864 | 0.04% | 2026-04-09 |
| Chris Francis SVP, Corporate Development, Head of Emer · +436,875 options |
Insider | 61,867 | 0.03% | 2026-02-26 |
| Heidi L Wagner Director · +64,000 options |
Insider | 55,630 | 0.03% | 2026-10-05 |
| Christopher I Wright Chief Medical Officer |
Insider | 45,625 | 0.02% | 2026-04-09 |
| Mark Corrigan Director · +140,200 options |
Insider | 39,515 | 0.02% | 2026-10-05 |
Share count 197,228,968 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for WVE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →